Pancreatic Cancer Research

ResearcherLeiden University Medical CenterActive in the last 2 years

Julie Earl

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-9360-4716; OpenAlex author ID A5072361619. Sources: OpenAlex.

Their work

Papers
39 (first author 3, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
167
Papers, trials and grants by year

2015: 3 papers · 2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 3 papers · 2021: 2 papers · 2022: 5 papers · 2023: 4 papers · 2024: 6 papers · 2025: 7 papers · 2026: 5 papers

Papers 39

  1. Pancreatic Cancer Early Detection Biomarkers for High-Risk Individuals: Insights From the PRECEDE Consortium. Last author DOI 10.1002/ijc.70592↗
  2. Publisher Correction: Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-026-69055-2↗
  3. A Comprehensive Assessment of the Causal Relationship between Atopic Conditions and Pancreatic Cancer Risk: A Two-Sample Mendelian Randomization Study. Co-author DOI 10.1158/1055-9965.epi-25-1601↗
  4. Predicting pancreatic cancer in high-risk individuals and in the general population: how long is the road yet? Last author DOI 10.17235/reed.2026.12183/2026↗
  5. High-fat diet imprints a macrophage-tumor CAMP-P2RX7 axis driving pancreatic cancer initiation, plasticity and metastasis Co-author DOI 10.64898/2026.02.10.703309↗
  6. Combined analysis of a serum mRNA/miRNA marker signature and CA 19-9 for timely and accurate diagnosis of recurrence after resection of pancreatic ductal adeno… Co-author DOI 10.1002/ueg2.12676↗
  7. Organoids, tissue slices and organotypic cultures: Advancing our understanding of pancreatic ductal adenocarcinoma through in vitro and ex vivo models. First author DOI 10.1016/j.semcancer.2024.12.003↗
  8. Leveraging epigenetic alterations in pancreatic ductal adenocarcinoma for clinical applications. Co-author DOI 10.1016/j.semcancer.2025.01.003↗
  9. Targeting pancreatic cancer screening by identification of pathogenic variants of BRCA2/ BRCA1 in healthy individuals who have no known family history of pancr… Co-author DOI 10.1016/j.semcancer.2025.05.001↗
  10. A plasma-based multimetabolite biomarker for early detection of pancreatic cancer Co-author DOI 10.1016/s2468-1253(25)00089-5↗
  11. Deciphering the role of complement system genes in pancreatic cancer susceptibility and prognosis. Co-author DOI 10.1038/s41467-025-65811-y↗
  12. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  13. The Spanish Familial Pancreatic Cancer Registry (PANGENFAM): a decade follow-up of individuals at high-risk for pancreatic cancer. Co-author DOI 10.1007/s10689-024-00388-x↗
  14. The best linear unbiased prediction (BLUP) method as a tool to estimate the lifetime risk of pancreatic ductal adenocarcinoma in high-risk individuals with no … Last author DOI 10.1007/s10689-024-00397-w↗
  15. The Peptidoglycan Recognition Protein 1 confers immune evasive properties on pancreatic cancer stem cells. Co-author DOI 10.1136/gutjnl-2023-330995↗
  16. Pancreatic cancer screening in high-risk individuals. Last author DOI 10.17235/reed.2024.10635/2024↗
  17. Should We Offer Universal Germline Genetic Testing to All Patients with Pancreatic Cancer? A Multicenter Study. Co-author DOI 10.3390/cancers16223779↗
  18. The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals. Co-author DOI 10.6004/jnccn.2023.7097↗
  19. Nanomedicine and epigenetics: New alliances to increase the odds in pancreatic cancer survival. Co-author DOI 10.1016/j.biopha.2023.115179↗
  20. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2021-325564↗
  21. Racial, Ethnic, and Sex-based Disparities among High-risk Individuals Undergoing Pancreatic Cancer Surveillance. Co-author DOI 10.1158/1940-6207.capr-22-0529↗
  22. Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue. Last author DOI 10.3791/65229↗
  23. Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis. Co-author DOI 10.1016/j.ebiom.2021.103797↗
  24. Standardization of EUS imaging and reporting in high-risk individuals of pancreatic adenocarcinoma: consensus statement of the Pancreatic Cancer Early Detectio… Co-author DOI 10.1016/j.gie.2021.10.025↗
  25. Timeline of Development of Pancreatic Cancer and Implications for Successful Early Detection in High-Risk Individuals. Co-author DOI 10.1053/j.gastro.2021.10.014↗
  26. Detection of Early-Stage Pancreatic Ductal Adenocarcinoma From Blood Samples: Results of a Multiplex Biomarker Signature Validation Study. Co-author DOI 10.14309/ctg.0000000000000468↗
  27. DNA Methylation Mediates EMT Gene Expression in Human Pancreatic Ductal Adenocarcinoma Cell Lines. Co-author DOI 10.3390/ijms23042117↗
  28. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS Negativity and a Longer O… Co-author DOI 10.3390/cancers13071612↗
  29. Correction: Earl et al. Somatic Mutation Profiling in the Liquid Biopsy and Clinical Analysis of Hereditary and Familial Pancreatic Cancer Cases Reveals KRAS N… Co-author DOI 10.3390/cancers13153687↗
  30. A comprehensive analysis of candidate genes in familial pancreatic cancer families reveals a high frequency of potentially pathogenic germline variants. Co-author DOI 10.1016/j.ebiom.2020.102675↗
  31. ISG15 and ISGylation is required for pancreatic cancer stem cell mitophagy and metabolic plasticity. Co-author DOI 10.1038/s41467-020-16395-2↗
  32. Epigenetic Landscape in Pancreatic Ductal Adenocarcinoma: On the Way to Overcoming Drug Resistance? First author DOI 10.3390/ijms21114091↗
  33. Tumor-associated macrophage-secreted 14-3-3ζ signals via AXL to promote pancreatic cancer chemoresistance. Co-author DOI 10.1038/s41388-019-0803-9↗
  34. Increased plasma levels of galectin-1 in pancreatic cancer: potential use as biomarker. Co-author DOI 10.18632/oncotarget.26034↗
  35. Refinement of screening for familial pancreatic cancer. Co-author DOI 10.1136/gutjnl-2015-311098↗
  36. Benefit of Surveillance for Pancreatic Cancer in High-Risk Individuals: Outcome of Long-Term Prospective Follow-Up Studies From Three European Expert Centers. Co-author DOI 10.1200/jco.2015.64.0730↗
  37. PanGen-Fam: Spanish registry of hereditary pancreatic cancer. Co-author DOI 10.1016/j.ejca.2015.07.004↗
  38. Circulating tumor cells (Ctc) and kras mutant circulating free Dna (cfdna) detection in peripheral blood as biomarkers in patients diagnosed with exocrine panc… Co-author DOI 10.1186/s12885-015-1779-7↗
  39. Biomarkers for early diagnosis of pancreatic cancer. First author DOI 10.1586/17474124.2015.965145↗

Closest collaborators

The 25 strongest of 167 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Alfredo Carrato · 21 shared papers, 2015–2025 · strength 2.21
  2. Bruno Sáinz · 9 shared papers, 2019–2026 · strength 1.15
  3. William Greenhalf · 5 shared papers, 2015–2026 · strength 0.90
  4. Daniele Campa · 3 shared papers, 2025–2026 · strength 0.85
  5. Ana García García de Paredes · 4 shared papers, 2024 · strength 0.78
  6. Božena Smolková · 5 shared papers, 2020–2025 · strength 0.74
  7. Randall E. Brand · 5 shared papers, 2022–2026 · strength 0.73
  8. Salvatore Paiella · 4 shared papers, 2022–2026 · strength 0.71
  9. Sonia Alcalá · 5 shared papers, 2019–2026 · strength 0.64
  10. Núria Malats · 6 shared papers, 2015–2025 · strength 0.61
  11. Carmen E. Guerra · 4 shared papers, 2022–2026 · strength 0.61
  12. Verona Buociková · 4 shared papers, 2022–2025 · strength 0.61
  13. Maria Urbanova · 4 shared papers, 2022–2025 · strength 0.61
  14. Eduardo Lobo · 5 shared papers, 2015–2024 · strength 0.55
  15. Diane M. Simeone · 3 shared papers, 2023–2026 · strength 0.49
  16. George Zogopoulos · 3 shared papers, 2023–2026 · strength 0.49
  17. Jennifer B. Permuth · 3 shared papers, 2023–2026 · strength 0.49
  18. Aimee Lee Lucas · 4 shared papers, 2022–2024 · strength 0.49
  19. Seçil Ak Aksoy · 2 shared papers, 2025 · strength 0.48
  20. Juan Carlos López-Gil · 3 shared papers, 2023–2026 · strength 0.47
  21. Enrique Vázquez-Sequeiros · 5 shared papers, 2015–2024 · strength 0.45
  22. Eithne Costello · 3 shared papers, 2015–2025 · strength 0.43
  23. Patricia Sancho · 3 shared papers, 2020–2026 · strength 0.42
  24. Bryson W. Katona · 3 shared papers, 2022–2024 · strength 0.39
  25. Daniel C. Chung · 3 shared papers, 2022–2024 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.